Progress of research on bone-vascular axis in chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2022.06.008

Abstract

Abstract:

Mineral and bone disorder (MBD) is a common complication in patients with chronic kidney disease (CKD). Renal osteodystrophy (ROD) and vascular calcification (VC) are its main clinical manifestations. At present, VC is considered to be an active regulation process of vascular smooth muscle cells transdifferentiation to osteoblast-like cell or chondroid cells. ROD and VC have similar pathogenesis, and there may be a "bone-vascular axis" crosstalk. This article mainly reviewed the related factors of the "bone-vascular axis" in ROD and VC of CKD-MBD, in order to find a better strategy to prevent CKD-MBD.

Key words: Chronic kidney disease, Bone diseases, Vascular calcification, Bone-vascular axis

Lin Xiong, Santao Ou. Progress of research on bone-vascular axis in chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(06): 342-346.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.06.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I06/342

Figures/Tables 1

References 48

[1]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) [J]. Kidney Int Suppl, 2017, 7(1): 1-59.
[2]	Evenepoel P, Opdebeeck B, David K, et al. Bone-vascular axis in chronic kidney disease [J]. Adv Chronic Kidney Dis, 2019, 26(6): 472-483.
[3]	Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J]. Genes Dev, 1998, 12(9): 1260-1268.
[4]	Oštrić M, Kukuljan M, Markić D, et al. Expression of bone-related proteins in vascular calcification and its serum correlations with coronary artery calcification score [J]. J Biol Regul Homeost Agents, 2019, 33(1): 29-38.
[5]	Huang QX, Li JB, Huang N, et al. Elevated osteoprotegerin concentration predicts increased risk of cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis [J]. Kidney Blood Press Res, 2020, 45(4): 565-575.
[6]	Znorko B, Oksztulska-Kolanek E, Michaowska M, et al. Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? a systematic review [J]. Adv Med Sci, 2017, 62(1): 52-64.
[7]	Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway [J]. Circ Res, 2009, 104(9): 1041-1048.
[8]	Lysitska A, Galanis N, Skandalos I, et al. Histology and immunohistochemistry of radial arteries are suggestive of an interaction between calcification and early atherosclerotic lesions in chronic kidney disease [J]. Medicina (Kaunas), 2021, 57(11): 1156.
[9]	Ozkok A, Caliskan Y, Sakaci T, et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients [J]. Clin J Am Soc Nephrol, 2012, 7(6): 965-973.
[10]	Luo J, Yang Z, Ma Y, et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption [J]. Nat Med, 2016, 22(5): 539-546.
[11]	Carrillo-López N, Martínez-Arias L, Alonso-Montes C, et al. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification [J]. Nephrol Dial Transplant, 2021, 36(4): 618-631.
[12]	Bisson SK, Ung RV, Mac-Way F. Role of the Wnt/β-catenin pathway in renal osteodystrophy [J]. Int J Endocrinol, 2018, 2018: 5893514.
[13]	De Maré A, Maudsley S, Azmi A, et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis [J]. Toxins, 2019, 11(7): 428.
[14]	Pietrzyk B, Wyskida K, Ficek J, et al. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients [J]. Int Urol Nephrol, 2019, 51(3): 519-526.
[15]	Ferreira AC, Cotovio P, Aires I, et al. The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients [J]. Calcif Tissue Int, 2022, 110(2): 215-224.
[16]	Wang XR, Yuan L, Zhang JJ, et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D [J]. Nephrology, 2017, 22(4): 286-292.
[17]	De Maré A, Opdebeeck B, Neven E, at al. Sclerostin protects against vascular calcification development in mice [J]. J Bone Miner Res, 2022, 37(4): 687-699.
[18]	Li X, Liu XL, Li X, et al. Dickkopf1 (Dkk1) alleviates vascular calcification by regulating the degradation of phospholipase D1 (PLD1) [J]. J Cardiovasc Transl Res, 2022, 15(6): 1327-1339.
[19]	柴文秀. 腹膜透析患者血清sclerostin和Dickkopf-1与腹主动脉钙化的关联性研究[D]．石家庄：河北医科大学，2018.
[20]	Rakipovski G, Rolin B, Barascuk N, et al. A neutralizing antibody against DKK1 does not reduce plaque formation in classical murine models of atherosclerosis: Is the therapeutic potential lost in translation? [J]. Atherosclerosis, 2020, 314: 1-9.
[21]	Benz K, Varga I, Neureiter D, et al. Vascular inflammation and media calcification are already present in early stages of chronic kidney disease [J]. Cardiovasc Pathol, 2017, 27: 57-67.
[22]	Henze LA, Luong TTD, Boehme B, et al. Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells [J]. Aging (Albany NY), 2019, 11(15): 5445-5462.
[23]	Lee HY, Lim S, Park S. Role of inflammation in arterial calcification [J]. Korean Circ J, 2021, 51(2): 114-125.
[24]	Wang Y, Galli M, Shade Silver A, et al. IL1β and TNFα promote RANKL-dependent adseverin expression and osteoclastogenesis [J]. J Cell Sci, 2018, 131(11): jcs213967.
[25]	Farquharson C, Berry JL, Mawer EB, et al. Ascorbic acid-induced chondrocyte terminal differentiation: the role of the extracellular matrix and 1，25-dihydroxyvitamin D [J]. Eur J Cell Biol, 1998, 76(2): 110-118.
[26]	Altaf FM, Hering TM, Kazmi NH, et al. Ascorbate-enhanced chondrogenesis of ATDC5 cells [J]. Eur Cell Mater, 2006, 12(7): 64-70.
[27]	Neven E, Dauwe S, De Broe ME, et al. Endochondral bone formation is involved in media calcification in rats and in men [J]. Kidney Int, 2007, 72(5): 574-581.
[28]	Cozzolino M. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation [J]. Nephrol Dial Transplant, 2012, 27(1): 122-127.
[29]	张萌萌，张秀珍，邓伟民，等. 骨代谢生化指标临床应用专家共识(2020)[J]. 中国骨质疏松杂志，2020, 26(6): 781-796.
[30]	McCabe KM, Zelt JG, Kaufmann M, et al. Calcitriol accelerates vascular calcification irrespective of vitamin K status in a rat model of chronic kidney disease with hyperphosphatemia and secondary hyperparathyroidism [J]. J Pharmacol Exp Ther, 2018, 366(3): 433-445.
[31]	Nguyen-Yamamoto L, Tanaka KI, St-Arnaud R, et al. Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification [J]. JCI Insight, 2019, 4(13): e126467.
[32]	Zheng Z, Shi H, Jia J, et al. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies [J]. BMC Nephrol, 2013, 14: 199.
[33]	熊琳，朱婷婷，张丽玲，等. 慢性肾病大鼠血管钙化与骨代谢标志物的相关性研究[J]. 中国比较医学杂志，2021, 31(1): 87-94.
[34]	Bjørklund G, Svanberg E, Dadar M, et al. The role of matrix Gla protein (MGP) in vascular calcification [J]. Curr Med Chem, 2020, 27(10): 1647-1660.
[35]	Evenepoel P, Claes K, Meijers B, et al. Poor vitamin K status is associated with low bone mineral density and increased fracture risk in end-stage renal disease [J]. J Bone Miner Res, 2019, 34(2): 262-269.
[36]	Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients [J]. BMC Nephrol, 2014, 15: 145.
[37]	El Borolossy R, El-Farsy MS. The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial [J]. Eur J Clin Nutr, 2022, 76(6): 848-854.
[38]	Tsai MT, Chen YY, Chang WJ, et al. Warfarin accelerated vascular calcification and worsened cardiac dysfunction in remnant kidney mice [J]. J Chin Med Assoc, 2018, 81(4): 324-330.
[39]	Alappan HR, Kaur G, Manzoor S, et al. Warfarin accelerates medial arterial calcification in humans [J]. Arterioscler Thromb Vasc Biol, 2020, 40(5): 1413-1419.
[40]	Lees JS, Chapman FA, Witham MD, et al. Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis [J]. Heart, 2019, 105(12): 938-945.
[41]	Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, et al. Chronic kidney disease-mineral and bone disorders: pathogenesis and management [J]. Calcif Tissue Int, 2021, 108(4): 410-422.
[42]	伍子贤，戴如璋，林少豪，等. 肾性骨病相关分子通路的研究进展[J]．中国骨质疏松杂志，2020, 26(1): 146-151.
[43]	Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis [J]. Am J Kidney Dis, 2016, 67(4): 559-566.
[44]	Evenepoel P, Bover J, Torres PU. Parathyroid hormone metabolism and signaling in health and chronic kidney disease [J]. Kidney Int, 2016, 90(6): 1184-1190.
[45]	Cheng SL, Shao JS, Halstead LR, et al. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/β-catenin signaling and aortic fibrosis in diabetic arteriosclerosis [J]. Circ Res, 2010, 107(2): 271-282.
[46]	Villa-Bellosta R, Egido J. Phosphate, pyrophosphate, and vascular calcification: a question of balance [J]. Eur Heart J, 2017, 38(23): 1801-1804.
[47]	Haarhaus M, Arnqvist HJ, Magnusson P. Calcifying human aortic smooth muscle cells express different bone alkaline phosphatase isoforms, including the novel B1x isoform [J]. J Vasc Res, 2013, 50(2): 167-174.
[48]	Yan J, Li L, Zhang M, et al. Circulating bone-specific alkaline phosphatase and abdominal aortic calcification in maintenance hemodialysis patients [J]. Biomark Med, 2018, 12(11): 1231-1239.

Please choose a citation manager

Content to export